Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sino Biopharmaceutical Limited

http://www.sinobiopharm.com/index.html#/

Latest From Sino Biopharmaceutical Limited

Biogen CEO Poses Million Dollar Question – Do We Need To Spend On Weight Loss Drugs?

As demand for Wegovy busts through capacity, Biogen’s Viehbacher asks if we need to spend on drugs for weight loss or other preventable diseases when the dollar could go towards non-preventable chronic diseases. Discussing investments at a recent conference, he was joined by Fidelity’s Rajiv Kaul who said the concept of therapeutic classes is outdated

Commercial Financing

Chinese Newcomers Look For Niche Immuno-Oncology Opportunities

Chinese pharma companies are continuing to pile into the already overcrowded domestic anti-PD-1/L1 sector in China, but despite the competition and regulatory tightening, the latecomers are looking for opportunities in areas such as cervical and small cell lung cancer with relatively fewer contenders.

China ImmunoOncology

Sino Biopharm Completes F-Star Acquisition After US CFIUS Review

Sino Biopharm's $161m all-cash acquisition of F-star has finally closed amid heightening US-China tensions and following completion the Chinese firm, through its UK subsidiary invoX, plans to expand its operations and presence at F-star’s UK headquarters.

China M & A

Akeso's Xia Looks Beyond Summit Deal To Independent Global Development, Sales

Last December, China's Akeso struck a major agreement worth up to $5bn with Summit Therapeutics, which set a new record in terms of total deal value for a single asset in the Chinese biopharma sector. Akeso founder and CEO Michelle Xia is now planning to pursue a more independent path in taking the firm global.

China Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Nutraceuticals
  • Biotechnology
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Beijing Tide Pharmaceutical Co Ltd, invoX Pharma
    • Jiangsu Chia Tai Tianqing Pharmaceutical Co Ltd, Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd, Qingdao Chia Tai Haier Pharmaceutical Co Ltd, Jiangsu Chia Tai Qing Jiang Pharmaceutical Co Ltd, etc. Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
UsernamePublicRestriction

Register